Here are the DEF 14A proxy statements from Oramed Pharmaceuticals Inc. (ORMP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ORMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORMP filings page.
Oramed Pharmaceuticals Inc. is asking stockholders to vote at its 2026 annual meeting on six main items: electing six directors for one-year terms, ratifying Kesselman & Kesselman (a PwC member firm) as auditor for 2026, approving an amendment to the Long-Term Incentive Plan, advisory Say on Pay and Say on Frequency votes, and a potential adjournment authority.
The incentive plan amendment would increase the shares of common stock authorized for issuance under the plan by 3,000,000, bringing the total to 12,500,000. The meeting is set for September 15, 2026, in Jerusalem, with a record date of July 20, 2026, when 41,597,354 shares of common stock were outstanding and entitled to vote. A significant related-party transaction with Lifeward Ltd. transferred Oramed’s POD technology into OraTech and, at closing, yielded Oramed 1,250,363 Lifeward ordinary shares, multiple warrant positions and $9.0 million of senior secured convertible notes, with an option for an additional $9.0 million of notes upon milestones.